💊FDA Approval Update | #FDA approved #Voyxact (#sibeprenlimab-szsi) for #IgAN to reduce #proteinuria
🌟#VISIONARY (a Phase III trial): achieved 50% reduction in proteinuria at 9 months
🔸MedChemExpress provides sibeprenlima for research use only

PANTHERx® Rare Partners with Otsuka for VOYXACT® Nephropathy Treatment PANTHERx® Rare Pharmacy joins Otsuka as the exclusive pharmacy to dispense VOYXACT®, a new treatment for IgA nephropathy aimed at reducing proteinuria in adults.

PANTHERx® Rare Partners with Otsuka for VOYXACT® Nephropathy Treatment #USA #Pittsburgh #IgA_nephropathy #PANTHERx_Rare #VOYXACT